Promising Urinary Microbiome Signals in Congenital Anomalies of Kidney and Urinary Tract, but not yet Ready for Clinical Risk Stratification Authors: Zhicheng Luo Published: 2026 To the Editor: Anand et al.1 describe preinfection urinary microbiome differences across controls and clinically stratified congenital anomalies of the kidney and urinary tract subgroups in Indian children and then relate baseline microbial features to subsequent urinary tract infection.1 This combination of baseline profiling and follow-up is a real strength and addresses a clear gap in pediatric data. Our reservation is not with the presence of a signal, but with how far the current findings are taken toward clinical application. At present, the study seems better suited to support a hypothesis-generating framework than for near-term risk stratification or management decisions. First, the prognostic interpretation remains preliminary. Only 14 urinary tract infections occurred among 36 children with congenital anomalies of the kidney and urinary tract, yet the manuscript moves from nonsignificant global baseline measures for later urinary tract infection (dysbiosis score, p = 0.20; Kendall-PCoA-1, p = 0.11) to multiple taxa-level prognostic claims, including 7 infinite hazard ratios.1 In sparse-event survival settings, such estimates can arise from monotone likelihood and usually warrant penalized modelling or a more cautious prognostic framing.2 Clarification of the follow-up timescale would also be helpful, because the text reports a median follow-up of 564 months, whereas Figure 2 is plotted in days. A second issue is how far the mechanistic and clinical interpretation can reasonably go from the assays used. Pediatric urinary microbiome composition varies with age, sex, and urologic history,3 and the congenital anomalies of the kidney and urinary tract group here was markedly younger than controls. More importantly, species-level inference from short-read V3–V4 16S data remains imperfect,4 whereas the metabolite and antimicrobial-resistance findings were inferred rather than directly measured at the sample level.1,5 These analyses are informative, but they do not yet provide a sufficient basis for patient-level decisions on prophylaxis, antimicrobial stewardship, or timing of intervention. We would therefore suggest a modest recalibration rather than a substantive retreat— describe these microbial signatures as candidate prognostic markers, clarify the time scale for the time-to-event analyses, and prioritize orthogonal validation with higher-resolution sequencing together with direct metabolomic or resistome assessment.2,4,5 Because urine is a low-biomass specimen, bringing the sampling route, negative controls, and decontamination workflow into the main text—details not reported there—would also make the findings easier to judge and easier to reproduce.5 Framed in this way, the study remains an important early contribution while giving readers a clearer sense of what is established and what still awaits confirmation. Disclosure All the authors declared no competing interests. Author Contributions ZL conceived the study, drafted and revised the manuscript, and approved the final manuscript. Declaration of AI and AI-Assisted Technologies in the Writing Process Generative AI tools were used solely for language refinement and formatting assistance. All scientific interpretation, critique, and scholarly content were independently developed by the authors. References